GeneArt™ Genomic Cleavage Detection Kit
Invitrogen™

GeneArt™ Genomic Cleavage Detection Kit

Das GeneArt Genomic Cleavage Detection Kit ist eine schnelle T7-Endonuklease I-basierte Methode zur Quantifizierung, wie gut Ihr Genome-Editing-Protokoll Insertionen undWeitere Informationen
Have Questions?
KatalognummerMenge
A2437220 reactions
Katalognummer A24372
Preis (EUR)
260,00
Each
Menge:
20 reactions
Preis (EUR)
260,00
Each
Das GeneArt Genomic Cleavage Detection Kit ist eine schnelle T7-Endonuklease I-basierte Methode zur Quantifizierung, wie gut Ihr Genome-Editing-Protokoll Insertionen und Deletionen (Indels) im Genom Ihrer Zelllinie verursacht. Dies ist der schnellste Weg, um die beste CRISPR-Cas9 gRNA oder die beste TAL-Effektornuklease für Ihr Zelltechnik-Experiment zu quantifizieren und zu validieren. Das GeneArt Genomic Cleavage Detection Kit bietet eine praktische, schnelle und vollständige Lösung.

Mit dieser T7-Endonuklease-I-Methode (T7EI) können Sie Ihre Effizienz bei der Genombearbeitung am Ziel, die durch nicht-homologe Endverbindungsaktivität (NHEJ) erzeugt wird, schnell und zuverlässig messen. Vorteile des GeneArt Genomic Cleavage Detection Kit:

• Minimale Vorbereitungszeit - PCR-Amplifikation aus Zelllysat, keine DNA-Aufreinigung erforderlich
• Kurze Protokolle - Vier Stunden von der Zellernte bis zu quantifizierten Ergebnissen
• Einfach PCR-Primer hinzufügen – alle erforderlichen Materialien in einer Box. Keine separaten PCR-Mastermixe oder DNA-Extraktionskits zu kaufen.
• Quantifizierung der Bearbeitungseffizienz direkt aus Ihrem Gel - die Dichte des Gelbands korreliert direkt mit der Bildung von Indel am Ziel

. Erhalten Sie Ergebnisse am selben Tag, ohne auf Sequenzierungsergebnisse oder komplizierte Sequenzierungsanalysen warten zu müssen.
Nur für Forschungszwecke. Nicht zur Verwendung bei diagnostischen Verfahren.
Specifications
FormatKit
Anzahl Reaktionen20 Reaktionen
PolymeraseTaq-Polymerase
ProdukttypGenom-Spaltungsnachweiskit
Menge20 reactions
ErkennungsstelleIndel
Ausreichend für20 Reaktionen
VerfahrenCRISPR-Cas9, TAL-Effektornuklease
NachweisverfahrenPrimer-Sonde
FormFlüssig
ReaktionsgeschwindigkeitSchnell
Unit SizeEach
Inhalt und Lagerung
Enthält:

• 1 Flasche Zelllysepuffer
• 1 Röhrchen Proteinase K
• 1 Röhrchen PCR-Supermix
• 1 Röhrchen Wasser
• 1 Röhrchen T7E1 Detektionsenzyme
• 1 Röhrchen T7E1 Detektionsreaktionspuffer
• 1 Röhrchen Kontroll-Template und Primer

Alle Komponenten bei -5 °C bis -30 °C lagern.

Häufig gestellte Fragen (FAQ)

What are TALs or TALENS?

TALs or TALENs are transcription activator-like effector nuclease proteins that are naturally occurring transcriptional activators secreted by Xanthomonas spp. into their plant hosts. GeneArt TALs are derived from Xathomonas TAL effectors, the DNA-binding domain of which consists of a variable number of amino acid repeats. Each repeat contains 33–35 amino acids and recognizes a single DNA base pair. The DNA recognition occurs via 2 hypervariable amino acid residues at positions 12 and 13 within each repeat, called repeat-variable di-residues (RVDs). TAL effector repeats can be assembled in modular fashion, varying the RVDs to create a TAL protein that recognizes a specific target DNA sequence.

What is CRISPR-STOP?

CRISPR-STOP is a method of inserting STOP codon sequences to generate knockouts.

Please refer to the following article: CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations.

Find additional tips, troubleshooting help, and resources within our Genome Editing Support Center.

I am working with TALs and want to incorporate an effector domain that you do not carry. What should I do?

We do offer a multiple cloning site sequence in the place of the effector domain sequence for our TAL MCS entry vector. This option allows you to insert any protein-coding sequence, and allows your resulting TAL protein to deliver the effector in a sequence-specific manner anywhere in the genome. We also provide gene synthesis services to generate any effector domain for which you don't have a template.

I am trying to design my TAL but do not have a T at the 5´ end of the TAL effector. What should I do?

While our Invitrogen GeneArt Precision TALs required a T at the 5´end and 13-18 bp spacing between the forward and reverse TAL effectors for proper pairing of Fok1 nucleases, the Invitrogen GeneArt PerfectMatch TALs allow for targeting of any sequence across the genome and eliminates the 5´ T constraints. Additionally, the spacing between the two effectors is optimal at 15-16 bp.

The binding domain for TALs can be either 19 or 25 bp in length. Does one work better than the other?

The 19 bp binding domains perform better for the nucleases. The binding sites do not need to be the same size; however, best performance for the nucleases is with the 19 bp binding domains.

Zitierungen und Referenzen (7)

Zitierungen und Referenzen
Abstract
CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C.
Authors:Tsukamoto K, Ozeki C, Kohda T, Tsuji T,
Journal:
PubMed ID:26177297
'Botulinum neurotoxins produced by Clostridium botulinum cause flaccid paralysis by inhibiting neurotransmitter release at peripheral nerve terminals. Previously, we found that neurons derived from the murine P19 embryonal carcinoma cell line exhibited high sensitivity to botulinum neurotoxin type C. In order to prove the utility of P19 cells for the ... More
Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.
Authors:Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S, Ravinder N, Chesnut JD,
Journal:
PubMed ID:26003884
'CRISPR-Cas9 systems provide a platform for high efficiency genome editing that are enabling innovative applications of mammalian cell engineering. However, the delivery of Cas9 and synthesis of guide RNA (gRNA) remain as steps that can limit overall efficiency and ease of use. Here we describe methods for rapid synthesis of ... More
Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system.
Authors:Sakuma T, Nishikawa A, Kume S, Chayama K, Yamamoto T,
Journal:
PubMed ID:24954249
CRISPR/Cas9-mediated genome editing is a next-generation strategy for genetic modifications, not only for single gene targeting, but also for multiple targeted mutagenesis. To make the most of the multiplexity of CRISPR/Cas9, we established a system for constructing all-in-one expression vectors containing multiple guide RNA expression cassettes and a Cas9 nuclease/nickase ... More
Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA.
Authors:Liang X, Potter J, Kumar S, Ravinder N, Chesnut JD
Journal:J Biotechnol
PubMed ID:27845164
'While CRISPR-based gene knock out in mammalian cells has proven to be very efficient, precise insertion of genetic elements via the cellular homology directed repair (HDR) pathway remains a rate-limiting step to seamless genome editing. Under the conditions described here, we achieved up to 56% targeted integration efficiency with up ... More
Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX.
Authors:Yu X, Liang X, Xie H, Kumar S, Ravinder N, Potter J, de Mollerat du Jeu X, Chesnut JD,
Journal:Biotechnol Lett
PubMed ID:26892225
'To identify the best lipid nanoparticles for delivery of purified Cas9 protein and gRNA complexes (Cas9 RNPs) into mammalian cells and to establish the optimal conditions for transfection. Using a systematic approach, we screened 60 transfection reagents using six commonly-used mammalian cell lines and identified a novel transfection reagent (named ... More